Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy

Middle East African Journal of Ophthalmology

Volumn 20, Issue 1, 2013, Pages 51-55

  Sato, Tatsuhiko ^a   Morita, Shin Ichi ^a   Bando, Hajime ^a   Sato, Shigeru ^a   Ikeda, Toshihide ^a   Emi, Kazuyuki ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Bevacizumab; Postoperative Vitreous Haemorrhage; Proliferative Diabetic Retinopathy; Vascular Endothelial Growth Factor; Vitrectomy

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; BLEEDING; CAUTERIZATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; HUMAN; IRIS DISEASE; IRIS NEOVASCULARIZATION; LASER COAGULATION; LENS IMPLANTATION; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; OPHTHALMOLOGICAL SURGICAL EQUIPMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PATIENT SELECTION; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETINA DETACHMENT; RETINA INJURY; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT DURATION; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

BEVACIZUMAB; POSTOPERATIVE VITREOUS HAEMORRHAGE; PROLIFERATIVE DIABETIC RETINOPATHY; VASCULAR ENDOTHELIAL GROWTH FACTOR; VITRECTOMY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84878780241     PISSN: 09749233     EISSN: 09751599     Source Type: Journal    
DOI: 10.4103/0974-9233.106387     Document Type: Article

References (21)

1. Dunn DR. Dissemination of the published results of an important clinical trial: An analysis of the citing literature. Bull Med Libr Assoc 1981;69:301-6.
2. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122-35.
3. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 1985;92:492-502.
4. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
5. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-8.
6. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
7. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004;22:1198.
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006;113:363-72.
9. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 2006;26:279-84.
10. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-25.
11. Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 2008;92:1450-5.
12. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008;246:837-42.
13. da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, et al. Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688-91.
14. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: A randomized clinical trial. Ophthalmology 2009;116:1943-8.
15. Lo WR, Kim SJ, Aaberg TM Sr, Bergstrom C, Srivastava SK, Yan J, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina 2009;29:926-31.
16. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927-38.
17. Inoue Y, Usui M, Ohashi Y, Shiota H, Yamazaki T, Preoperative Disinfection Study Group. Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: A prospective randomized multicenter study. Jpn J Ophthalmol 2008;52:151-61.
18. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 1982;15:635-9.
19. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9.
20. Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology 2004;111:1880-4.
21. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118:2218-26.